AXIM Biotechnologies (AXIM) 10-Q 13 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	14-May-15
Document and Entity Information:
Entity Registrant Name	AXIM BIOTECHNOLOGIES, INC.
Entity Trading Symbol	AXIM
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Entity Central Index Key	1514946
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		34,018,000
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$195,254	$661,128
Prepaid expenses	35,343	72,329
Loan receivable	5,000	5,000
Total current assets	235,597	738,457
TOTAL ASSETS	235,597	738,457
Current liabilities:
Accounts payable and accrued liabilities	181,893	144,385
Due to shareholder	5,000	5,000
Convertible loan	50,000	50,000
Due to first insurance funding	13,609	54,020
Due to related party	36,764	65,775
Promissory note - related party	1,000,000	1,000,000
Total current liabilities	1,287,266	1,319,180
STOCKHOLDERS' DEFICIT
Preferred stock, $0.0001 par value, 5,000,000 shares authorized; 1,000,000 issued and outstanding	100	100
Common stock, $0.0001 par value, 300,000,000 shares authorized 33,018,000 and 33,000,000 shares issued and outstanding, respectively;	3,302	3,300
Additional paid in capital	143,839	107,841
Accumulated deficit	-1,198,910	-691,964
TOTAL STOCKHOLDERS' DEFICIT	-1,051,669	-580,723
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$235,597	$738,457

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets Parentheticals (USD $)	Mar. 31, 2015	Dec. 31, 2014
Parentheticals
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares issued	1,000,000	1,000,000
Preferred Stock, shares outstanding	1,000,000	1,000,000
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	33,018,000	33,000,000
Common Stock, shares outstanding	33,018,000	33,000,000

Condensed_Consolidated_Stateme

Condensed Consolidated Statement of Operations (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Expenses:
Total operating expenses	$488,818	$7,528
Loss from operations	($488,818)	($7,528)
Other Income and Expense:
Interest expense	18,128
Total Other Income and Expense	18,128
Loss from Continuing operation before provision of income tax	-506,946	-7,528
Provision for income taxes	0
LOSS FROM CONTINUING OPERATION	-506,946	-7,528
LOSS FROM DISCONTINUED OPERATION		-93
NET LOSS	($506,946)	($7,621)
Loss per common share from continuing operation- basic and diluted	($0.02)	$0
Loss per common share from discontinued operation- basic and diluted	$0	$0
Loss per common share - basic and diluted	($0.02)	$0
Weighted average common shares outstanding - basic and diluted	33,018,000	33,000,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders' Deficit (unaudited) (USD $)	Common Stock Shares	Common Stock Amount	Preferred Stock Shares	Preferred Stock Amount	Additional Paid In Capital	Accumulated Deficit	Total
						USD ($)	USD ($)
Balance at Dec. 31, 2014	33,000,000	3,300	1,000,000	100	107,841	-691,964	-580,723
Common Stock Issued	18,000	2			35,998		36,000
Net Loss-March 31, 2015						($506,946)	($506,946)
Balance at Mar. 31, 2015	33,018,000	3,302	1,000,000	100	143,839	-1,198,910	-1,051,669

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss)	($506,946)	($7,621)
Loss from discontinued operation		-93
Loss from continuing operation	-506,946	-7,528
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based Compensation	36,000
Change in operating assets and liabilities:
Accounts payable and accrued expenses	37,507	1,401
Prepaid expenses	36,986
Change in due to first insurance funding	-40,410
Change in due to related party	-29,011
NET CASH USED IN OPERATING ACTIVITIES OF CONTINUING OPERATION	-465,874	-6,127
NET CASH PROVIDED BY OPERATING ACTIVITIES OF DISCONTINUED OPERATION		6,000
NET CASH USED IN OPERATING ACTIVITIES	-465,874	-127
CASH FLOWS FROM INVESTING ACTIVITIES:
NET CASH USED IN INVESTING ACTIVITIES OF CONTINUING OPERATION	0
NET CASH USED IN INVESTING ACTIVITIES	0
CASH FLOWS FROM FINANCING ACTIVITIES:
NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATION	-465,874	-127
NET CASH PROVIDED BY FINANCING ACTIVITIES OF DISCONTINUED OPERATION	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	-465,874	-127
NET CHANGE IN CASH	-465,874	-127
CASH BALANCES
Beginning of period	661,128	127
End of period	195,254
CASH PAID DURING THE PERIOD FOR:
Interest	0	0
Income taxes	$0	$0
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING TRANSACTIONS
Gain on settlement of debt transferred to additional paid in capital	0	96141

ORGANISATION

ORGANISATION	3 Months Ended
	Mar. 31, 2015
ORGANISATION
ORGANISATION	NOTE 1:  ORGANIZATION
	The Company was originally incorporated in Nevada on November 18, 2010, as Axim International Inc.  On July 24, 2014, the Company changed its name to AXIM Biotechnologies, Inc. to better reflect its business operations.  The Company’s principal executive office is located at 18 East 50th Street, 5th Floor, New York, NY 10022.   On August 7, 2014, the Company formed a wholly owned Nevada subsidiary named Axim Holdings, Inc.  This subsidiary will be used to help facilitate the anticipated activities planned by the Company.
	In early 2014, the Company discontinued its organic waste marketable by-product business to focus on its anticipated new business to become an innovative biotechnology company working on the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids based products as well as focusing on research, development and production of pharmaceutical, nutriceutical and cosmetic products as well as procurement of genetically and nano-controlled active ingredients.

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2015
BASIS OF PRESENTATION:
BASIS OF PRESENTATION	NOTE 2:  BASIS OF PRESENTATION:
	The unaudited condensed consolidated financial statements of AXIM Biotechnologies, Inc. (formerly Axim International, Inc.) as of March 31, 2015, and for the three months period ended March 31, 2015 and 2014 have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”).
	The following (a) balance sheets as of March 31, 2015 (unaudited) and December 31, 2014, which have been derived from audited financial statements, and (b) the unaudited interim statements of operations and cash flows of AXIM Biotechnologies, Inc. (the "Company") have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 14, 2015.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
SIGNIFICANT ACCOUNTING POLICIES:
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3: SIGNIFICANT ACCOUNTING POLICIES
	Use of estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates.
	Cash equivalents
	The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
	Revenue Recognition
	The Company recognizes revenue on four basic criteria that must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the fee charged for services rendered and products delivered and the collectability of those fees. Revenue is generally recognized upon shipment.
	Revenue recognized during the three months ended March 31, 2015 and 2014 related to sales of product of $0 and $2,500, respectively, which is included in loss from discontinued operations.
	Principles of consolidation
	The unaudited condensed consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiary Axim Holdings, Inc. as of March 31, 2015. All significant intercompany transactions and balances have been eliminated in consolidation.
	Fair value of financial instruments
	The Company follows paragraph 825-10-50-10 Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
	Income taxes
	The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date.
	The Company adopted section 740-10-25 of the FASB Accounting Standards Codification ("Section 740-10-25"). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25.
	Net loss per common share
	Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be ant dilutive.
	Recently issued accounting standards
	In June of 2014 the Financial Accounting Standards Board issued Accounting Standards Update ASU 2014-10, “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	In August, 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties About an Entities Ability to Continue as a Going Concern. The standard is intended to define management’s responsibility to decide whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The standard requires management to decide whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The standard provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the footnotes. The standard becomes effective in the annual period ending after December 15, 2016, with early application permitted. The adoption of this pronouncement is not expected to have a material impact on the financial statements.  Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 7.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	The Company has elected to adopt the provisions of ASU 2014-10 for the year ending December 31, 2014. The adoption of ASU 2014-10 did not have a significant impact on our results of operations, financial condition or cash flow.
	Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

PROMISSORY_NOTE_RELATED_PARTY

PROMISSORY NOTE - RELATED PARTY	3 Months Ended
	Mar. 31, 2015
PROMISSORY NOTE - RELATED PARTY
PROMISSORY NOTE - RELATED PARTY	NOTE 4:  PROMISSORY NOTE - RELATED PARTY
	On August 8, 2014 the Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC (CCB), a related party (the owners of  CCB also own 90% of the outstanding shares of the Company), under which it borrowed $1,000,000 to fund working capital. The loan is a demand note which bears interest at a rate of 7% annually.
	The following table summarizes promissory note payable as of March 31, 2015 and December 31, 2014:
			March 31,		December 31,
			2015		2014
	Promissory note payable, due on demand, interest at 7%	$	1,000,000	$	1,000,000
	Accrued interest		45,553		28,053
		$	1,045,553	$	1,028,053
	The Company recognized interest expense of $17,500 and $0 for the three months ended March 31, 2015 and 2014 respectively, included in Accounts payable and accrued liabilities.

COMMON_STOCK

COMMON STOCK	3 Months Ended
	Mar. 31, 2015
COMMON STOCK
COMMON STOCK	NOTE 5: COMMON STOCK
	On January 15, 2015, the Company issued 18,000 shares of common stock as compensation for services performed for the Company by certain directors of the Company. The fair value of the underlying stock on the date of issuance was at $2.00 per share.  The Company determined the fair value of the common stock was more readily determinable than the fair value of the services rendered. For the three months ended March 31, 2015, the Company recorded $36,000 of compensation expense in the accompanying unaudited condensed consolidated statement of operations.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2015
RELATED PARTY TRANSACTIONS:
RELATED PARTY TRANSACTIONS	NOTE 6:  RELATED PARTY TRANSACTIONS
	Effective November 26, 2012, the Company entered into a separate Convertible Loan Agreement with its ex-President, under which it borrowed $50,000, in the form of a non-interest bearing note.  In January 2015, this note was extended until June 30, 2015 under the same terms.  The loan is convertible into common stock at $0.10 per share at the option of the lender any time after February 28, 2013.  As of March 31, 2015 the loan has not been converted.  The Company used the proceeds of this loan to fund the purchase of license rights under the November 26, 2012, agreement with Omega Research Corporation. During the year 2014, the Convertible Loan was transferred to a third party
	On May 21, 2014, the Company President advanced an additional $5,000 to the Company to fund working capital needs.  This brings the total amount due to shareholder to $55,000 as of March 31, 2015, including convertible loan.
	On August 8, 2014, the Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC (CCB), a related party (The owners of  CCB also own 90% of the outstanding shares of the Company), under which it borrowed $1,000,000 to fund working capital. The loan is a demand note which bears interest at a rate of 7% annually. For the three months ended March 31, 2015 the Company charged $17,500 as interest expenses to operation (refer note 4).
	On June 25, 2014, the Company received a non interest bearing advance from CCB of $30,000 to pay the down payment on its D & O liability insurance. In addition the Company during the year 2014 was advanced an additional $35,775 for operating expenses principally for the owner’s salary. This advance is non-interest bearing and is due on demand. The total outstanding due to related party as of March 31, 2015 and December 31, 2014 is $36,764 and $65,775, respectively.

GOING_CONCERN

GOING CONCERN	3 Months Ended
	Mar. 31, 2015
GOING CONCERN:
GOING CONCERN	NOTE 7:  GOING CONCERN
	The Company’s unaudited condensed consolidated financial statements have been presented assuming that the Company will continue as a going concern.  As shown in the unaudited condensed consolidated financial statements, the Company has negative working capital of $1,051,669, has an accumulated deficit of $1,198,910, has cash used in operating activities of continuing operations $465,874 and presently does not have the resources to accomplish its objectives during the next twelve months. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.
	The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

DUE_TO_FIRST_INSURANCE_FUNDING

DUE TO FIRST INSURANCE FUNDING	3 Months Ended
	Mar. 31, 2015
DUE TO FIRST INSURANCE FUNDING
DUE TO FIRST INSURANCE FUNDING	NOTE 8:  DUE TO FIRST INSURANCE FUNDING
	The Company financed the purchase of its D & O insurance with a note due to First Insurance Funding.  The principal amount financed was $120,000. Interest is due on the unpaid balance at a rate of 6.189% per annum.  The total amount of interest due under the terms of the note is $3,116. The term of the note is nine months commencing August 25, 2014.  Payments are due for nine installments in the amount of $13,680, which includes principal and interest, commencing August 25, 2014. The total outstanding due to First Insurance Funding as of March 31, 2015 and December 31, 2014 is $13,609 and $54,020, respectively.

COMMITMENT_AND_CONTINGENCIES

COMMITMENT AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
COMMITMENT AND CONTINGENCIES
COMMITMENT AND CONTINGENCIES	NOTE 9:  COMMITMENT AND CONTINGENCIES
	On June 13, 2014, the Company entered into an employment agreement with Dr. George Anastassov, its Chief Executive Officer, Chief Financial Officer and Secretary. The agreement’s effective date is June 1, 2014. The initial term of the agreement is one year.  The agreement renews each year until terminated by the Company or Dr. Anastassov. Cash remuneration is $20,000 per month payable bi-monthly. Following 12 months of continuous employment the agreement calls for a 500,000 share restricted stock grant of the Company’s common shares, or at the sole option of the Company, its cash equivalent based on the ten day average closing price of the company’s common stock immediately preceding the grant date, as quoted on Yahoo Finance.com. Following 15 months of continuous employment and every three months thereafter the agreement calls for a 125,000 share restricted stock grant of the Company’s common shares, or at the sole option of the Company, its cash equivalent based on the ten day average closing price of the company’s common stock immediately preceding the grant date, as quoted on Yahoo Finance.com
	On November 15, 2014 the Company and Municipality of Almere, the Netherlands entered into a “reservation agreement” whereas the Company is interested in the construction of a factory for the production of a new drug, on the plots of building and land located at Lagekant, the Netherlands. The reservation agreement is for a term of one year and expires on November 15, 2015. The Company must notify the Municipality of Almere whether or not it wishes to be considered for the purchase of the building and land on or before the end of the reservation agreement. If the municipality has not received notification on time before the end of the reservation period whether it wishes to purchase the building and land and also does not receive notification during the three (3) working days following said date, the right to reservation of the Company lapses. The municipality is then fully at liberty to offer the building land to any other prospective purchasers. The Company is entitled to terminate this agreement in writing without this giving rise to any payment obligation. The Company will incur a reservation fee after February 15, 2015 in the amount of 49,284 Euros.The purchase price has been determined to be 985,680 euro’s exclusive of VAT and transfer taxes.

SUBSEQUENT_EVENT

SUBSEQUENT EVENT	3 Months Ended
	Mar. 31, 2015
SUBSEQUENT EVENT
SUBSEQUENT EVENT	NOTE 10: SUBSEQUENT EVENT
	On May 1, 2015 the Company has entered into a licensing agreement with CanChew Biotechnologies, LLC (“Canchew”).  The agreement provides that in exchange for its’ intellectual property Canchew will receive 5,826,706 restricted shares of Company common stock and sliding scale royalties based on gross receipts as follows in the chart below:
	Year	Percent
		(%)
	1	2
	2	2.2
	3	2.4
	4	2.6
	5	2.8
	Jun-50	3

ACCOUNTING_POLICIES_POLICIES

ACCOUNTING POLICIES (POLICIES)	3 Months Ended
	Mar. 31, 2015
ACCOUNTING POLICIES (POLICIES):
Use of Estimates, Policy	Use of estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates.
Cash Equivalents, Policy	Cash equivalents
	The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
Revenue Recognition, Policy	Revenue Recognition
	The Company recognizes revenue on four basic criteria that must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the fee charged for services rendered and products delivered and the collectability of those fees. Revenue is generally recognized upon shipment.
	Revenue recognized during the three months ended March 31, 2015 and 2014 related to sales of product of $0 and $2,500, respectively, which is included in loss from discontinued operations.
Principles of consolidation	Principles of consolidation
	The unaudited condensed consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiary Axim Holdings, Inc. as of March 31, 2015. All significant intercompany transactions and balances have been eliminated in consolidation.
Fair Value of Financial Instruments, Policy	Fair value of financial instruments
	The Company follows paragraph 825-10-50-10 Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value, and expands disclosures about fair value measurements
Income Taxes, Policy	Income taxes
	The Company follows Section 740-10, Income tax (“ASC 740-10”) Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date.
	The Company adopted section 740-10-25 of the FASB Accounting Standards Codification ("Section 740-10-25"). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25.
Net loss per common share	Net loss per common share
	Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share (“ASC 260-10”) of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be ant dilutive.
Recently issued accounting standards	Recently issued accounting standards
	In June of 2014 the Financial Accounting Standards Board issued Accounting Standards Update ASU 2014-10, “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation” (“ASU 2014-10”). The amendments in ASU 2014-10 remove the definition of a development stage entity from the master glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	In August, 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties About an Entities Ability to Continue as a Going Concern. The standard is intended to define management’s responsibility to decide whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The standard requires management to decide whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The standard provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations in the footnotes. The standard becomes effective in the annual period ending after December 15, 2016, with early application permitted. The adoption of this pronouncement is not expected to have a material impact on the financial statements.  Management’s evaluations regarding the events and conditions that raise substantial doubt regarding the Company’s ability to continue as a going concern have been disclosed in Note 7.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations.
	The Company has elected to adopt the provisions of ASU 2014-10 for the year ending December 31, 2014. The adoption of ASU 2014-10 did not have a significant impact on our results of operations, financial condition or cash flow.
	Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

PROMISSORY_NOTE_RELATED_PARTY_

PROMISSORY NOTE - RELATED PARTY (TABLES)	3 Months Ended
	Mar. 31, 2015
PROMISSORY NOTE - RELATED PARTY (TABLES)
PROMISSORY NOTE - RELATED PARTY (TABLES)	The following table summarizes promissory note payable as of March 31, 2015 and December 31, 2014:
			March 31,		December 31,
			2015		2014
	Promissory note payable, due on demand, interest at 7%	$	1,000,000	$	1,000,000
	Accrued interest		45,553		28,053
		$	1,045,553	$	1,028,053

SUBSEQUENT_EVENT_TABLES

SUBSEQUENT EVENT (TABLES)	3 Months Ended
	Mar. 31, 2015
SUBSEQUENT EVENT (TABLES):
SUBSEQUENT EVENT (TABLES)	The agreement provides that in exchange for its’ intellectual property Canchew will receive 5,826,706 restricted shares of Company common stock and sliding scale royalties based on gross receipts as follows in the chart below:
	Year	Percent
		(%)
	1	2
	2	2.2
	3	2.4
	4	2.6
	5	2.8
	Jun-50	3

REVENUE_DETAILS

REVENUE (DETAILS) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue
Sales of product	$0	$2,500

RELATED_PARTY_PROMISSORY_NOTE_

RELATED PARTY PROMISSORY NOTE (DETAILS) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Aug. 08, 2014
Related party Promissory note
Promissory note payable, due on demand, interest at 7%	$1,000,000	$1,000,000
Accrued interest on note	45,553	28,053
Total amount of note payable	1,045,553	1,028,053
CCB own outstanding shares of the Company			90.00%
Working capital fund			$1,000,000
Interest rate annually			7.00%

INTEREST_EXPENSE_DETAILS

INTEREST EXPENSE (DETAILS) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Interest expense {1}
Company recognized interest expense	$17,500	$0

COMMON_STOCK_DETAILS

COMMON STOCK (DETAILS) (USD $)	Mar. 31, 2015	Jan. 15, 2015
Common Stock Details
Company issued shares of common stock		18,000
Fair value of stock per share		$2
Company recorded compensation expense	36,000

RELATED_PARTY_AGREEMENTS_DETAI

RELATED PARTY AGREEMENTS (DETAILS) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Aug. 08, 2014	Jun. 25, 2014	21-May-14
Related party agreements
Company president advanced to fund working capital needs					$5,000
Company entered into a separate Convertible Loan Agreement with its President and borrowed	50,000
The loan is convertible into common stock at a price per share	$0.10
Total amount due to shareholder including convertible loan	55,000
CCB own outstanding shares			90.00%
Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC and borrowed to fund working capital			1,000,000
Interest rate on note			7.00%
Interest expense charged by the company in the period	17,500
Company received a non interest bearing advance from CCB				30,000
Advanced an additional operating expenses				35,775
Total outstanding due to related party	$36,764	$65,775

GOING_CONCERN_DETAILS

GOING CONCERN (DETAILS) (USD $)	Mar. 31, 2015
GOING CONCERN DETAILS
Company has negative working capital	$1,051,669
Incurred accumulated deficit in the period	1,198,910
Cash used in operating activities of continuing operations	$465,874

FIRST_INSURANCE_FUNDING_DETAIL

FIRST INSURANCE FUNDING (DETAILS) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Aug. 25, 2014
First Insurance Funding
The principle amount financed			$120,000
Interest due on the unpaid balance at a rate per annum			6.19%
The total amount of interest due under the terms of the note			3,116
Payments are due for nine installments in the amount and includes principle and interest			13,680
Total outstanding due to First Insurance Funding	$13,609	$54,020

EMPLOYMENT_AGREEMENT_AND_COMMI

EMPLOYMENT AGREEMENT AND COMMITMENTS (DETAILS) (USD $)	Jun. 13, 2015	Feb. 15, 2015
Employment agreement and commitments
Cash remuneration in the amount per month payable bi-monthly	$20,000
Restricted stock grant of the Company's common shares granted employment the agreement	500,000
Following 15 months of continuous employment and every three months thereafter the agreement Restricted stock granted	125,000
Reservation fee in euros		49,284
Purchase price exclusive of VAT and transfer taxes in euros		$985,680

SUBSEQUENT_TRANSACTIONS_DETAIL

SUBSEQUENT TRANSACTIONS (DETAILS)	1-May-15
Subsequent Transactions
Canchew will receive restricted shares of common stock	5,826,706
Royalties of 1 year	2.00%
Royalties of 2 year	2.20%
Royalties of 3 year	2.40%
Royalties of 4 year	2.60%
Royalties of 5 year	2.80%
Royalties of 6 to 50 years	3.00%